FDA label
What is rabeprazole used for?
The FDA-approved uses of rabeprazole, quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for rabeprazole lists 7 uses: Healing of Erosive or Ulcerative GERD in Adults; Maintenance of Healing of Erosive or Ulcerative GERD in Adults; Treatment of Symptomatic GERD in Adults; Healing of Duodenal Ulcers in Adults; and 3 more.
Run it in Rivvi
Which 2027 plans near you dropped or restricted rabeprazole?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Rabeprazole Sodium, tablet, delayed release
Indications and Usage, quoted from the label by Torrent Pharmaceuticals Limited (ANDA202376). Cross-references to other label sections are left out.
Healing of Erosive or Ulcerative GERD in Adults
Rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered.
Maintenance of Healing of Erosive or Ulcerative GERD in Adults
Rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months.
Treatment of Symptomatic GERD in Adults
Rabeprazole sodium delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks.
Healing of Duodenal Ulcers in Adults
Rabeprazole sodium delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks.
Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults
Rabeprazole sodium delayed-release tablets, in combination with amoxicillin and clarithromycin as a three drug regimen, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted.
Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults
Rabeprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Treatment of Symptomatic GERD in Adolescent Patients 12 Years of Age and Older
Rabeprazole sodium delayed-release tablets are indicated for the treatment of symptomatic GERD in adolescents 12 years of age and above for up to 8 weeks.
Source: DailyMed label, set id 04e88b86-e1dd-4c56-8359-45fbcc161f7d, version 18, effective July 27, 2026. NDC 13668-107, one of 37 listings for this product.
Questions
What is rabeprazole used for?
The FDA label for rabeprazole lists 7 uses: Healing of Erosive or Ulcerative GERD in Adults; Maintenance of Healing of Erosive or Ulcerative GERD in Adults; Treatment of Symptomatic GERD in Adults; Healing of Duodenal Ulcers in Adults; and 3 more.
What drug class is rabeprazole?
FDA lists rabeprazole in the Proton Pump Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.